FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

HINDUNILVR Consensus Forecast

No. of reports in last year
29
No. of analysts
13
Average Consensus Forecast
2150.86
Consensus Potential
-0.76%

HINDUNILVR Price Target Potential

BrokerageTargetPotential
Geojit Financial Services22002.19%
Sharekhan23056.65%
Hem Securities241010.72%
Motilal Oswal242011.08%
ICICIdirect.com22504.37%

HINDUNILVR Targets in FrontPage Forums

6 Users have submitted 7 trade ideas of Rs. 143,302.6 for HINDUNILVR
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

HINDUNILVR Ratings

Long term HINDUNILVR rating by FrontPage users
4.5/5 (18 Ratings)

29 HINDUNILVR share price target reports by brokerages below. See what is analyst's view on HINDUNILVR share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. HINDUNILVR Forum
  3. HINDUNILVR Price Target

HINDUNILVR Share Price Target

HINDUNILVR Share Price Target - Broker Reports - 2020

7-May-20
Price @ Call: 1936.76
Target: 2200
HOLD
8-May-20
Price @ Call: 2061.93
Target: 2305
BUY
9-May-20
Price @ Call: 2061.93
Target: 2410
ACCUMULATE
Company is currently operating at about 70% of normative levels and is hopeful to improve this in the coming days. Company have ramped up capacities in key categories such as sanitizers, handwash etc. Company is also operating with shorter planning cycles, stepping up agility and building resilience in the supply chain. Company have ramped up production of hand sanitizers by a factor of 60x from the pre-COVID level. Domestic Consumer Growth declined by 9% with a decline of 7% in Underlying Volume Growth. Reported EBITDA margin reduced by 40 bps (160 bps reduction on comparable basis after adjusting for accounting impact of Ind AS 116). Profit after tax (PAT) was lower by 1%. For FY 2019-20, Domestic Consumer Growth was 2% with Underlying Volume Growth of 2%. Company’s EBITDA margin improved by 100 bps on comparable basis, PAT (bei)*, grew by 11% to Rs. 6743 Cr. and PAT at Rs. 6738 Cr. was up by 12%. Recommended a final dividend of Rs. 14/- for the financial year ended 31st March, 2020 on Equity Shares of Re. 1/- each. The Company had earlier paid an interim dividend of Rs. 11/- per share on 5th November, 2019. The total dividend for the said period amounts to Rs. 25/- per Equity Share of face value of Re. 1/- each.
... Read more
1-May-20
Price @ Call: 2200.83
Target: 2420
BUY
We remain positive on HUVR from a medium-term perspective due to (a) best of breed earnings growth potential beyond the near term owing to its portfolio and execution strengths, (b) significant synergies in FY22E as a result of GSKCH, and (c) its RoCE levels being well ahead of peers. All these factors mean that premium multiples are likely to sustain. We plan to move our forecasts to merged numbers (which is likely to add over 10% to FY22E EPS due to the nature of the GSK merger and synergies) once HUVR completes the revaluation of GSKCH assets. At 55x merged EPS, we get a TP of INR2,420; Maintain Buy.
... Read more
2-May-20
Price @ Call: 2200.83
Target: 2250
HOLD
The unprecedented turn of events and its negative impact on supply chain & discretionary products demand is expected to result in a revenue decline (comparable) in FY21E. However, we believe the company has many levers to protect its margins and propel growth once the situation come back to normal. HUL remains one of our preferred plays in the consumption space with its ability to weather the storm. We maintain HOLD recommendation with a revised target price of Rs 2250/share.
... Read more
1-May-20
Price @ Call: 2200.83
Target: 1969
REDUCE
HUL posted weak performance across all fronts in 4QFY20 despite our estimates being lower than consensus. Revenue and volume decline of 9% and 7% was impacted by weak BPC market growth and lockdown led trade destocking in March. Lockdown led supply chain disturbance will be resolved in the coming months. However, underlying demand which was already reeling in FY20 will be further impacted in FY21. Consumer trends are expected to change sharply for many categories in FY21. Discretionary, OOH consumption and rural will remain tepid. In our recent thematic report (link), we have already cut down estimates for our coverage universe. However, we expect there can be more downside risk to our estimates for all. We cut our EPS estimates for HUL by 7-8% for FY21 and FY22. We value HUL at 47x on Mar-22E EPS, our TP is at Rs 1,969 (earlier 2,113). Maintain REDUCE.
... Read more
24-Mar-20
Price @ Call: 2023.75
Target: 2310
BUY
The acquisition of Vwash would not make any material difference to growth. However, it has strong potential to grow into a bigger brand in the next five to 10 years. With respect to the recent outbreak of Covid-19, the personal wash category is likely to see strong growth in the next few quarters. Though the personal wash category is fully penetrated, it is expected to witness unprecedented increase in per capita consumption after increasing awareness on personal hygiene. Despite the extraordinary economic slowdown, HUL is likely to sustain robust revenue growth and strong operating margins. The company would continue to command a premium to the peers being the leader in the category. We change our recommendation from HOLD to BUY with a target price of Rs 2310/share.
... Read more
23-Mar-20
Price @ Call: 1891.83
Target: 2136
ACCUMULATE
HUL continues to face sluggish demand in 4Q although COVID19 is resulting in strong pickup in demand for Hygiene products like soaps, wandwash, sanitizers, floor cleaners etc. Discretionary personal care products are facing pressure on demand as Covid 19 is reducing the incidence of going out. HUL is ramping up production of hygiene related products which should benefit the company in the coming months, however the benefits will be negated by reduction in prices of sanitizers and increased CSR allocation in view of COVID19. HUL has not taken any major price adjustments despite recent crude decline given volatile pricing scenario. Near term visibility looks hazy given uncertainty on COVID19, however we believe that expected demand recovery from 1QFY21 will be for sure pushed back to 2HFY21. We believe acquisition of VWash brand from Glenmark is positive although it is unlikely to have material impact on the numbers. Despite near term challenges, we remain positive on HUVR’s ability to gain from 1) ability to straddle though products and price points 2) maximum range of new generation products (handwash, body/face wash, hair conditioners, green tea, liquid detergents) 3) most agile and efficient supply chain, focus on digital and analytics for distribution and sales. HUL trades at 40.3x FY22 EPS (Post Glaxo Merger) of Rs46.4 with 15% PAT CAGR. HUL remains one of the best defensive plays in the current uncertain scenario despite rich valuations. Retain Accumulate.
... Read more
1-Feb-20
Price @ Call: 2074.93
Target: 2445
BUY
There is minor change to our FY20/FY21/FY22 EPS forecasts. We continue to remain positive on HUVR considering that the company is fairly competitive and in a strong position to deliver above market growth. Volume delivery has been ahead of its much smaller peers and margins visibility could help sustain such premium valuations in the current environment, supported by best earnings growth visibility in the Indian FMCG space with the highest return ratios. After incorporating GSKCH merger, the opportunity becomes even more attractive, as we see earnings growing at a CAGR of 26% over FY20-22, without assuming any synergy benefits in our margin estimates (will wait for more clarity). On a target multiple of ~54x September’21 EPS (assigning higher multiple for the expected margin benefit from synergy), we derive a TP of Rs 2,445. Maintain Buy.
... Read more
1-Feb-20
Price @ Call: 2034.15
Target: 2136
ACCUMULATE
We estimate 13.9% Adj. PAT CAGR over FY20-22 (14.9% including GSK Merger) and value the stock at 46xFY22 pro-forma EPS (including GSK acquisition) to arrive at a target price of Rs2136 (earlier Rs2057 based on 46xFY22 EPS). We believe Unilever’s intent to acquire GSK’s holding in HUL post-merger can re-rate the stock. Retain Accumulate.
... Read more
6-Jan-20
Price @ Call: 1928.75
Target: 2175
BUY
HUVR offers relative comfort in earnings growth in the consumer Staples space: HUVR has constantly expanded EBITDA margin each year (over the past 8 years) and has industry leading return ratios, led by its focus on cost-efficiency plans & premuimization. It offers most visibility (~18% earnings CAGR over FY19-21E) in the FMCG-staples packs with multiple drivers for growth with its (a) WIMI strategy, (b) strong execution, (c) thrust on Naturals portfolio, (d) focus on premiumization and market development to drive profitability improvement, (e) extensively employing technology and data analytics to remain ahead of competition. We recommend a BUY with TP of Rs 2,175.
... Read more

HINDUNILVR Share Price Target - Broker Reports - 2019

18-Dec-19
Price @ Call: 1922.88
Target: 2185
BUY
Valuation – Maintain Buy with a revised PT of Rs. 2,185: We have reduced our earnings estimates for FY2020E and FY2021E by ~3% each to factor in sustained slowdown in the demand environment, especially in rural geographies. We have introduced FY2022E estimates in this note. The stock has corrected by 10% in the past one month, which factors in the near-term headwind of slower revenue growth in rural markets. Hence, there is very limited downside risk from the current level. However, the long-term growth story of HUL is intact. Hence, we maintain our Buy recommendation on the stock with a revised price target (PT) of Rs. 2,185 (valuing the stock at 49x average of FY2021-FY2022 earnings estimates).
... Read more
12-Dec-19
Price @ Call: 2009.12
Target: 2378
BUY
Four key trends are particularly relevant to HUVR as they point toward an elevated earnings growth trajectory compared to the past. These include (a) rapidly improving adaptability to market requirements, (b) recognition and strong execution of the Naturals segment, (c) a continuous strong trend toward premiumization, and (d) extensive plans to employ technology, creating further entry barriers. Once we incorporate the GSKCH merger (no clarity on the date yet), there could be 8-9% addition to EPS in FY21, which means that the stock trades at ~45.1x FY21E v/s 49.1x as it appears now. Given HUVR’s best earnings growth visibility in the Indian large-cap consumer space and by far the highest return ratios, we believe that the premium valuations are justified. On a target multiple of 50x Dec’21E EPS, we derive a TP of INR2,378/share.
... Read more
18-Oct-19
Price @ Call: 2107.32
Target: 2210
HOLD
Company’s demand based approach and constant effort to improve operational efficiency has been a catalyst to topline growth and improved margins even during sluggish economic conditions, hence we believe the premium valuation is justified. We further move up the target price to Rs. 2,210 based on 55x adj. EPS FY21, while maintaining HOLD rating on the stock.
... Read more
16-Oct-19
Price @ Call: 2071.43
Target: 2240
BUY
HUL registered decent performance in H1FY2020, with volume growth of 5% in the domestic business and sustained improvement in OPM. Large savings because of cut in the corporate tax rate will be utilised behind innovations and supply chain. The company has paid interim dividend of Rs. 11 per share. We have broadly maintained our earnings estimates for FY2020/FY2021. We maintain our Buy recommendation on the stock with an unchanged PT of Rs. 2,240.
... Read more
14-Oct-19
Price @ Call: 2015.9
Target: 2250
BUY
We envisage HUL to be key beneficiary of the anticipated rural recovery and herbal- push, and expect its decent volume growth to sustain. With the push-for-premium sustaining, we expect better earnings growth. Rolling forward the valuation leads to TP of INR2,250 (55x, 12-month forward PE). We maintain ‘BUY/SO’. At CMP, the stock is trading at 49.2x FY21E EPS.
... Read more
14-Oct-19
Price @ Call: 2015.9
Target: 2265
BUY
Revenue was in line, while the margin surprised yet again.
Once we incorporate the GSKCH merger (final approvals awaited), there could be 8-9% addition to EPS in FY21, which means that the stock is trading at ~45.3xFY21 v/s 49.4x as it appears currently. Given its best-of-breed earnings visibility and by far highest return ratios, the premium valuations are justified. On a target multiple of 50x Sep’21E EPS, we derive a TP of INR2,265.
... Read more
15-Oct-19
Price @ Call: 2014.7
Target: 2310
BUY
HUVR’s results were above our estimate but after adjusting for slightly higher corporate taxrate, there is -2%/-0.6%/0.8% change in our FY20/FY21/FY22 EPS forecasts. We continue to remain positive on HUVR considering that the company is fairly competitive and in a strong position to deliver above market growth. Importantly, once we incorporate the GSKCH merger (likely in 4QFY20 now), there could be ~8% addition to EPS in FY21, which means that the stock is actually trading at ~45x FY21 v/s 49x FY21 that appears currently. We believe the premium valuations are justified as the company has the best earnings growth visibility in the Indian FMCG space, and also, the highest return ratios. On a target multiple of 51x Sep’21 EPS, we derive a TP of Rs.2,310 and maintain Buy rating.
... Read more
15-Oct-19
Price @ Call: 2014.7
Target: 2083
ACCUMULATE
We estimate 12.4% Adj. PAT CAGR over FY19-22 (12.7% including GSK Merger) and value the stock at 46xFY22 pro-forma EPS (including GSK acquisition) to arrive at a target price of Rs2083 (earlier Rs1967 based on 46xJune21 EPS). Retain Accumulate.
... Read more
10-Oct-19
Price @ Call: 1966.51
Target: 2135
BUY
26-Jul-19
Price @ Call: 1736
Target: 1950
BUY
Outlook & Valuation – Maintain BUY; But FY21 Earning Estimate Trimmed As the Company expects growth to pick-up pace in 2HFY20, we marginally trim our revenue estimate by 3%/4% for FY20E/FY21E to factor in weak performance in 1HFY20E. We tweak our EBITDA/PAT estimate by +2.5%/+2.5% for FY20E factoring heathy operational performance in 1QFY20 and revise our FY21E EBITDA/PAT estimate by -2.6%/-2.6% due to limited room for further cost savings going ahead. We believe HUVR’s outperformance is sustainable, as the demand scenario bottoms out and picks-up cyclically. We maintain our BUY recommendation on the stock, valuing it at 48x of FY21E earnings at Rs1,950.
... Read more
25-Jul-19
Price @ Call: 1728
Target: 1900
HOLD
Valuation & Outlook: On a high base and visible signs of slowdown, the company posted 5% volume growth during the quarter. Though we believe slower growth would continue for a few more quarters, with 26% operating margins and current A&P spend, the company has the largest war chest to propel growth. However, valuations at 50x FY21E provide little headroom for strong upside. Hence, we maintain our HOLD rating with a target price of 1900.
... Read more
25-Jul-19
Price @ Call: 1728
Target: 1830
HOLD
HUVR is well positioned over medium term to grow ahead of industry backed by agility and leveraging data analytics moat besides, 1) focus on premiumization, 2) strengthening the core, 3) distribution expansion, 4) market development and 5) cost saving initiatives. Besides, GSK Consumer’s merger by end of CY2019 could elevate growth rates further. We revise our TP to Rs. 1,830 (48x FY21E EPS) to factor in near term revenue slowdown.
... Read more
25-Jul-19
Price @ Call: 1728
Target: 1980
BUY
Considering that the company is in a fairly competitive and strong position to deliver above market expectations growth, despite the uncertainties, we prefer to retain our Buy rating on the stock after making slight revisions in our estimates with a revised target price (TP) of Rs1,980 (from Rs2,000 earlier) after marginally moderating our assumptions with an unchanged target multiple of 48x.
... Read more
24-Jul-19
Price @ Call: 1693.2
Target: 1990
BUY
HUL’s Q1FY2020 performance was largely in-line with expectations, with mid-single digit volume growth and low double- digit PAT growth. Management expects the volume growth trajectory to improve in H2FY2020 on account of likely improvement in demand environment. We have broadly maintained our earnings estimates for FY2020/FY2021. The stock has corrected by ~8% from its recent high and is currently trading at 42.6x its FY2021E earnings. We maintain our Buy recommendation on the stock with an unchanged price target (PT) of Rs. 1,990.
... Read more
24-Jul-19
Price @ Call: 1693.2
Target: 1970
BUY
We believe the premium valuations are justified as the company has the best earnings growth visibility in the large-cap Indian consumer space, and also, the highest return ratios so far. On a target multiple of 48x Jun’21 EPS, we derive a TP of INR1,970, with 16% upside.
... Read more
24-Jul-19
Price @ Call: 1693.2
Target: 1877
ACCUMULATE
HUL is likely to benefit from the expected rise in the government’s rural expenditure (farm loan waiver, rural stimulus, etc.). We maintain our FY20E and FY21E EPS at Rs 33.5 and Rs 37.6 and TP of Rs 1,877 (50x FY21E). Maintain Accumulate.
... Read more
23-Jul-19
Price @ Call: 1678.75
Target: 1816
ACCUMULATE
Benign competitive environment, improved product mix and cost efficiencies gives us comfort to increase our EBIDTA margin estimates by 30bps over FY19-21 (110bps expansion) leading to 1.3% and 0.6% increase in EPS estimates for FY20 and FY21. We estimate FY21 pro-forma EPS including GSK acquisition of Rs38.3 and value the stock at 46xJune21 arriving at target price of Rs1816. We strongly advise Accumulating HUL in uncertain markets.
... Read more
11-Jul-19
Price @ Call: 1717.85
Target: 2250
BUY
13-Jun-19
Price @ Call: 1837.4
Target: 2070
BUY
In our view, this valuation premium should sustain, given the company’s best earnings growth FII Includes depository receipts visibility in the large-cap Indian consumer space and by far the highest return ratios. On a target multiple of 50x Jun'21E EPS, we maintain our Buy rating and target price of INR2,070.
... Read more
11-Jun-19
Price @ Call: 1842.91
Target: 1900
HOLD
In a bid to outperform the industry in the medium to long term, HUL is focusing on digitisation and data analytics to increase its connectivity with distributors and end consumers, which would help drive future growth. In addition, GSK Consumer acquisition should also drive HUL's revenue growth considering lower penetration of malt based beverages and HUL’ssuperior capabilities to distribute it in a much deeper retail network. We keep our estimates intact with revenue, PAT CAGR of 14.1%, 16.3%, respectively, in FY19-21E. The company has generated a free cash flow of ~Rs 6,000 crore and healthy return ratios (RoCE: 85.3%, RoNW: 80.9%) in FY19, which justifies its rich valuation multiples. We maintain our HOLD recommendation on the stock with a target price of Rs 1,900 per share.
... Read more
10-Jun-19
Price @ Call: 1831.6
Target: 2070
BUY
HUVR is likely to continue outperforming on the volumes front v/s smaller players. Compared to the past, four key trends can drive an elevated earnings growth trajectory: (1) rapidly improving adaptability to market requirements, (2) recognition and strong execution on Naturals and other evolving categories, (3) continuous strong premiumization trend, and (4) extensive employment of technology, creating further entry barriers. Notably, if we incorporate the GSKCH merger (no date clarity yet) in our estimates, it will result in a 10-12% addition to EPS in FY21 which means that the stock is trading closer to 41x FY21 EPS (v/s over 46x it appears currently). We believe that its premium valuations should stay given the company's best earnings growth visibility in the large-cap Indian consumer space and by far the highest return ratios. On a target multiple of 50x Jun'21 EPS, we derive a TP of INR2,070. Maintain Buy.
... Read more
10-Jun-19
Price @ Call: 1831.6
Target: 2100
BUY
We expect HUL to deliver competitive top line and profitability growth and intensive market development efforts could provide further impetus to this in 2019. We retain Buy rating on the stock with a revised target price of Rs2,100 implying an upside of 15% from CMP. Our TP is based on modestly revised earnings multiple of 50x considering that inflation outlook is somewhat benign and market conditions could see improvement as inclusive growth is a significant priority for the new government.
... Read more
20-May-19
Price @ Call: 1759.99
Target: 1875
BUY
On the whole, we believe, HUVR’s consistent performance led by modest margin expansion could be driven by 1) focus on premiumization, 2) strengthening the core, 3) distribution expansion, 4) leveraging data analytics, 5) market development and 6) cost saving initiatives. Besides, GSK Consumer’s mergershall contribute from H2FY20 onwards and will elevate growth rates further. We retain BUY rating with a revised TP of Rs. 1,875(48x FY21E EPS)
... Read more
6-May-19
Price @ Call: 1666.5
Target: 1890
BUY
Estimates cut; Maintain Buy recommendation: We have cut our growth estimates by ~2% across categories which has resulted in 6% reduction in FY20/21E earnings. While the growth risks are systemic in nature, HUL continues to outperform the market. The company with a highly diversified portfolio has been able to manage a very stable growth profile. We believe HUL’s outperformance is sustainable. Valuing the company at 45x FY21E earnings at Rs 1890, we maintain Buy recommendation.
... Read more
7-May-19
Price @ Call: 1672.35
Target: 1900
HOLD
Despite rising input cost pressure, we believe higher growth from improving volumes and pricing actions along with HUL’s cost efficiencies provide visibility for future earnings growth. We estimate HUL will report revenue, PAT CAGR of 14%, 16.3%, respectively, in FY19-21E. Though HUL-GSKCH merger would bring in significant synergy benefits, valuations at 50x FY21E provide little headroom for strong upside. Hence, we maintain our HOLD recommendation with a target price of Rs 1900.
... Read more
6-May-19
Price @ Call: 1692.8
Target: 1990
BUY
Valuation – Maintain Buy with a revised TP of Rs1990: We have reduced our earnings estimates marginally by 2.3%/1.6% for FY2020/21 to factor in lower than earlier expected revenue growth. HUL will continue to deliver decent earning growth as it has a strong portfolio of brands in some of the leading categories and strong distribution base. Further, the recent acquisition of GSK Consumers’ domestic health food business will scale up HUL’s food business and will help it grow in the double digits in the near to medium term. We expect HUL’s earning to grow at CAGR of 18% over FY2019-21. HUL’s stock price is currently trading at 42.5x its FY2019E earnings. We maintain our Buy recommendation on the stock with a revised price target of Rs1990 (in-line with reduction of FY2021E estimates).
... Read more
6-May-19
Price @ Call: 1692.8
Target: 1575
REDUCE
3-May-19
Price @ Call: 1701.88
Target: 1804
NEUTRAL
HUL reported a healthy quarter (in-line) in the context of challenging macros. Notwithstanding its scale, HUL maintained growth leadership over the last 6 quarters (10% volume growth) led by strong product portfolio and remarkable execution. We continue to maintain our NEUTRAL rating since we downgraded in Jul-18 (stock is flat since then) as we don’t see any near-term trigger. We value HUL at 45x on FY21 EPS arriving at a TP of Rs 1,804.
... Read more
4-May-19
Price @ Call: 1701.88
Target: 1764
HOLD
Although 4Q volume growth has moderated to 7%, we believe that it is temporary given expectations of normal monsoons and benefit of PM Kisan Yojana to farmers in due course. We remain positive on HUVR given 1) sustained Premiumisation in Home Care, 2) success in naturals led by Lever Ayush, Indulekha and variants across brands 3) strong growth in emerging categories (premium laundry, hand wash, Liquid dish wash, Hair conditioner, Face-wash and Green tea) 4) synergy gains from acquisition of Glaxo Consumer healthcare in distribution and costs and 5) gains from supply chain, data analytics and efficient inventory management. We estimate pro- forma EPS (including GSK acquisition) of Rs38.2 for FY21 and value the stock at 46x thus arriving at target price of Rs1764. We expect back ended returns given lifetime high valuations. Hold.
... Read more
18-Mar-19
Price @ Call: 1698.65
Target: 2125
HOLD
There is no change to our forecasts. A combination of continued healthy volume growth v/s peers and better earnings growth compared to its own past record, aligned with best-in-breed return ratios, and synergies from the GSKCH acquisition from FY21 onwards (we are not building in benefit from the acquisition yet in our numbers), will lead to sustained high multiples. We maintain BUY rating on the stock with a target price of INR2,125, target multiple of 52x FY2021 EPS (~15% premium to 3-year average due to significantly improving business fundamentals).
... Read more
14-Mar-19
Price @ Call: 1745.35
Target: 2000
BUY
On a reverse DCF valuation methodology, the implied revenue growth is pegged at 10 per cent over the next 20 years with a steady-state EBIT margin of 22 per cent, which we believe is achievable. Considering HUL is most coveted Indian FMCG company, we believe an exit multiple of 30x is justifiable. While current valuation appears to be expensive, we believe it to be justified on the back of superior growth prospects led by highly diversified portfolio and macro tailwinds. We value the stock at 45 x FY21E earnings, which is 10 per cent discount to FY20E multiple to arrive at 1-year forward target price of Rs 2,000.
... Read more
14-Feb-19
Price @ Call: 1798.95
Target: 2120
BUY
Continued healthy volume growth (despite a challenging base) and strong EBITDA growth (despite absence of significant price increases) augur well for sustainability of its earnings growth. HUVR’s consistent and superior volume growth outperformance, even when compared with much smaller players, provides huge comfort. We expect this trend to continue, offering the best visibility among staples from a volumes growth perspective. Four key trends are particularly relevant to HUL; resulting in an elevation in its earnings growth trajectory of ~20% compared to the past, these include: (1) rapidly improving adaptability to market requirements, as exemplified by its WIMI strategy, (2) recognition and strong execution on Naturals, (3) continuous strong trend towards premiumization, and (4) extensive plans to employ technology, creating further entry barriers. HUVR not only offers the best earnings growth visibility in the large-cap Indian consumer space, but also has by far the highest return ratios, justifying premium valuations. On a target multiple of 54x Dec’20E EPS (~20% premium to three-year average due to significantly improving business fundamentals), we derive a TP of INR2,120. Maintain Buy.
... Read more
22-Jan-19
Price @ Call: 1748.3
Target: 2025
BUY
22-Jan-19
Price @ Call: 1748.3
Target: 1900
HOLD
21-Jan-19
Price @ Call: 1748.43
Target: 2071
BUY
21-Jan-19
Price @ Call: 1743.7
Target: 1855
NEUTRAL
18-Jan-19
Price @ Call: 1750.1
Target: 1877
ACCUMULATE
17-Jan-19
Price @ Call: 1767.59
Target: 2120
BUY
18-Jan-19
Price @ Call: 1750.1
Target: 1874
HOLD
11-Jan-19
Price @ Call: 1758.7
Target: 2138
BUY

HINDUNILVR Share Price Target - Broker Reports - 2018

12-Dec-18
Price @ Call: 1795.2
Target: 2250
BUY
3-Dec-18
Price @ Call: 1794.85
Target: 2071
BUY
4-Dec-18
Price @ Call: 1817.13
Target: 1855
NEUTRAL
4-Dec-18
Price @ Call: 1817.13
Target: 2030
BUY
4-Dec-18
Price @ Call: 1825.9
Target: 2140
BUY
3-Dec-18
Price @ Call: 1794.85
Target: 1880
HOLD
23-Oct-18
Price @ Call: 1567.31
Target: 1724
BUY
15-Oct-18
Price @ Call: 1520.17
Target: 1900
BUY
12-Oct-18
Price @ Call: 1561.98
Target: 1615
HOLD
16-Oct-18
Price @ Call: 1526.6
Target: 1800
BUY
12-Oct-18
Price @ Call: 1561.98
Target: 1767
BUY
15-Oct-18
Price @ Call: 1568.65
Target: 1500
SELL
15-Oct-18
Price @ Call: 1561.98
Target: 1691
NEUTRAL
12-Oct-18
Price @ Call: 1561.98
Target: 1900
BUY
12-Oct-18
Price @ Call: 1561.98
Target: 1703
HOLD
12-Oct-18
Price @ Call: 1561.98
Target: 1848
ACCUMULATE
12-Oct-18
Price @ Call: 1561.98
Target: 1900
BUY
18-Sep-18
Price @ Call: 1604.05
Target: 2025
BUY
11-Sep-18
Price @ Call: 1589.82
Target: 1900
BUY
19-Jul-18
Price @ Call: 1643.8
Target: 1800
ACCUMULATE
17-Jul-18
Price @ Call: 1753.85
Target: 1800
HOLD
17-Jul-18
Price @ Call: 1753.85
Target: 1605
SELL
17-Jul-18
Price @ Call: 1753.85
Target: 1950
BUY
17-Jul-18
Price @ Call: 1753.85
Target: 1887
HOLD
17-Jul-18
Price @ Call: 1753.85
Target: 2010
BUY
7-Jun-18
Price @ Call: 1573
Target: 1840
BUY
6-Jun-18
Price @ Call: 1563.9
Target: 1627
ACCUMULATE
15-May-18
Price @ Call: 1525.55
Target: 1647
HOLD
15-May-18
Price @ Call: 1504.95
Target: 1605
ACCUMULATE
15-May-18
Price @ Call: 1504.95
Target: 1805
BUY
16-Mar-18
Price @ Call: 1297.5
Target: 1515
BUY
1-Mar-18
Price @ Call: 1316.35
Target: 1518
HOLD
18-Jan-18
Price @ Call: 1368.2
Target: 1520
ACCUMULATE
18-Jan-18
Price @ Call: 1371.85
Target: 1518
HOLD
18-Jan-18
Price @ Call: 1371.85
Target: 1500
ACCUMULATE
18-Jan-18
Price @ Call: 1371.85
Target: 1514
BUY
18-Jan-18
Price @ Call: 1371.85
Target: 1585
BUY

HINDUNILVR Share Price Target - Broker Reports - 2017

20-Dec-17
Price @ Call: 1352
Target: 1570
BUY
14-Dec-17
Price @ Call: 1316.55
Target: 1387
BUY
13-Dec-17
Price @ Call: 1315
Target: 1500
BUY
1-Nov-17
Price @ Call: 1256.14
Target: 1400
BUY
30-Oct-17
Price @ Call: 1257
Target: 1392
ACCUMULATE
26-Oct-17
Price @ Call: 1265.29
Target: 1401
BUY
26-Oct-17
Price @ Call: 1273.55
Target: 1400
BUY
26-Oct-17
Price @ Call: 1273.55
Target: 1290
BUY
26-Oct-17
Price @ Call: 1273.55
Target: 1291
HOLD
26-Oct-17
Price @ Call: 1273.55
Target: 1440
BUY
26-Sep-17
Price @ Call: 1246.35
Target: 1270
BUY
24-Sep-17
Price @ Call: 1240.29
Target: 1400
BUY
22-Aug-17
Price @ Call: 1194
Target: 1350
BUY
19-Jul-17
Price @ Call: 1158
Target: 1304
BUY
19-Jul-17
Price @ Call: 1156
Target: 1296
BUY
24-Jul-17
Price @ Call: 1158
Target: 1250
BUY
18-Jul-17
Price @ Call: 1158
Target: 1253
HOLD
5-Jun-17
Price @ Call: 1086
Target: 1120
HOLD
5-Jun-17
Price @ Call: 1097
Target: 1106
HOLD
14-Jun-17
Price @ Call: 1102.6
Target: 1165
HOLD
18-May-17
Price @ Call: 1009
Target: 1140
BUY
18-May-17
Price @ Call: 1009
Target: 1120
BUY
18-May-17
Price @ Call: 991.25
Target: 930
SELL
17-May-17
Price @ Call: 1009
Target: 1106
HOLD
4-May-17
Price @ Call: 950
Target: 1010
BUY
24-Jan-17
Price @ Call: 862
Target: 978
BUY
24-Jan-17
Price @ Call: 862
Target: 925
NEUTRAL
24-Jan-17
Price @ Call: 863
Target: 924
ACCUMULATE
23-Jan-17
Price @ Call: 862
Target: 935
HOLD

HINDUNILVR Share Price Target - Broker Reports - 2016

10-May-16
Price @ Call: 865.8
Target: 800
SELL
27-Oct-16
Price @ Call: 842
Target: 924
ACCUMULATE
27-Oct-16
Price @ Call: 843
Target: 910
HOLD
27-Oct-16
Price @ Call: 843
Target: 870
ACCUMULATE
18-Jul-16
Price @ Call: 933.85
Target: 1100
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • HINDUNILVR Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,220.67
    Upside Target 22,204.33
    Upside Target 12,189.02
    Pivot2,172.68
    Downside Target 12,157.37
    Downside Target 22,141.03
    Downside Target 32,125.72
  • HINDUNILVR Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,262.38
    Upside Target 22,231.17
    Upside Target 12,202.43
    Pivot2,171.22
    Downside Target 12,142.48
    Downside Target 22,111.27
    Downside Target 32,082.53
  • HINDUNILVR Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,381.18
    Upside Target 22,290.57
    Upside Target 12,235.28
    Pivot2,144.67
    Downside Target 12,089.38
    Downside Target 21,998.77
    Downside Target 31,943.48
  • HINDUNILVR Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,204.33
    Upside Target 22,192.24
    Upside Target 12,184.77
    Pivot2,172.68
    Downside Target 12,160.59
    Downside Target 22,153.12
    Downside Target 32,141.03
  • HINDUNILVR Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,231.17
    Upside Target 22,208.27
    Upside Target 12,194.12
    Pivot2,171.22
    Downside Target 12,148.32
    Downside Target 22,134.17
    Downside Target 32,111.27
  • HINDUNILVR Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,290.57
    Upside Target 22,234.83
    Upside Target 12,200.4
    Pivot2,144.67
    Downside Target 12,088.93
    Downside Target 22,054.5
    Downside Target 31,998.77
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020